Insulin Analog Mid Mixture — Competitive Intelligence Brief

Insulin Analog Mid Mixture (Insulin Analog Mid Mixture) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin analog mixture. Area: Diabetes.

marketed Insulin analog mixture Insulin receptor Diabetes Small molecule

Target snapshot

Insulin Analog Mid Mixture (Insulin Analog Mid Mixture) — Eli Lilly and Company. This insulin analog mixture mimics natural insulin by binding to insulin receptors to promote glucose uptake and utilization in cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Analog Mid Mixture TARGET	Insulin Analog Mid Mixture	Eli Lilly and Company	marketed	Insulin analog mixture	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin analog mixture class)

1. Eli Lilly and Company · 1 drug in this class